At-a-glance comparison
| Feature |
Wegovy 2.4 mg injection |
Wegovy 7.2 mg injection |
Wegovy pill (25 mg) |
| Drug |
Semaglutide |
Semaglutide |
Semaglutide |
| Drug class |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
| Manufacturer |
Novo Nordisk |
Novo Nordisk |
Novo Nordisk |
| Maintenance dose |
2.4 mg once a week |
7.2 mg once a week |
25 mg once a day |
| How to take it |
An injection under the skin, any time of day, any day of the week, with or without food |
An injection under the skin, any time of day, any day of the week, with or without food |
A tablet on an empty stomach, with up to 120 ml of water, followed by a 30-minute wait before food, drinks, or other oral medications |
| Average weight loss in trials |
14.9% over 68 weeks (STEP 1)2 |
20.7% over 72 weeks (STEP UP)1 |
13.6% over 64 weeks (OASIS 4)3 |
| Most common side effects |
Nausea, diarrhoea, vomiting, constipation |
Nausea, diarrhoea, vomiting, constipation |
Nausea, vomiting, diarrhoea |
| Time to maintenance dose |
About 16 weeks |
About 28 weeks |
About 12 weeks |
| UK status (May 2026) |
Licensed; available privately, with some NHS access |
MHRA-approved January 2026 (single-injection pen approved April 2026); available privately |
Under MHRA review, decision expected late 2026 |
| FDA approval |
June 2021 |
March 2026 |
22 December 2025 |
Same molecule, three formats
All three Wegovy products contain semaglutide.
Semaglutide mimics GLP-1, a hormone our body produces in the gut after eating, which slows stomach emptying and signals fullness to the brain.
People on any of the three formats typically describe a noticeable reduction in food noise within the first few weeks.
The three formats differ in two ways: dose and delivery.
The 2.4 mg and 7.2 mg injections deliver semaglutide just under the skin, where it’s absorbed slowly and reliably over several days.
The dose difference is what produces the difference in weight loss. 7.2 mg is roughly three times the 2.4 mg dose, and this higher GLP-1 exposure translates into greater weight loss in trials.
The pill has to survive stomach acid and cross the gut wall, neither of which peptide drugs like semaglutide tolerate well on their own.
To make the oral version work, Novo Nordisk pairs semaglutide with a small molecule called SNAC (salcaprozate sodium). SNAC creates a small protected zone in the stomach lining where semaglutide can briefly cross into the bloodstream.
The pill requires a daily dose of 25 mg to produce roughly the same effect as the 2.4 mg weekly injection, because much of each oral dose doesn’t reach the bloodstream.
Average weight loss in trials
The three formats haven’t been directly compared in a single trial.
The closest like-for-like comparison comes from the three Phase 3 registration studies (large human trials with hundreds to thousands of participants): STEP 1 for the 2.4 mg injection, STEP UP for the 7.2 mg injection, and OASIS 4 for the pill.
STEP 1 randomised 1,961 adults with overweight or obesity (without type 2 diabetes) to Wegovy 2.4 mg or placebo for 68 weeks, alongside lifestyle support.
Participants on Wegovy lost an average of 14.9% of their starting body weight, compared with 2.4% on placebo. Around 86% achieved at least 5% weight loss.2
STEP UP randomised 1,407 adults with obesity (without type 2 diabetes) to Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo for 72 weeks.
Participants on the 7.2 mg dose lost an average of 20.7% of their starting body weight, compared with 17.5% on the 2.4 mg dose and 3.9% on placebo.
Over 90% of participants on 7.2 mg achieved at least 5% weight loss, and around one in three achieved at least 25%.1
The 20.7% figure is the trial regimen estimate, which reflects the result for participants who remain on treatment. The intention-to-treat figure, which includes everyone who joined the trial regardless of adherence, was 18.7%.
OASIS 4 randomised 307 adults with overweight or obesity (without type 2 diabetes) to the Wegovy pill or placebo for 64 weeks, alongside lifestyle support.
Participants on the pill lost an average of 13.6% of their starting body weight, compared with 2.2% on placebo.3
OASIS 4 reported two weight-loss figures in the same paper, and both are valid in different contexts.
The 13.6% is the intention-to-treat result, which includes everyone who enrolled in the trial, regardless of whether they completed it.
Among participants who remained on the pill and reached the maintenance dose, the average weight loss was 16.6%.3
We use the 13.6% figure throughout our guides because it reflects what tends to happen across a real-world group rather than only the people who complete a full course.
The practical takeaway from the three trials is that the 2.4 mg injection and the pill produce broadly similar weight loss, with the injection a percentage point or so ahead.
The 7.2 mg injection sits well clear of both, with around 7 percentage points more weight loss than the pill and around 6 percentage points more than the 2.4 mg injection.
If you’re choosing between the 7.2 mg and 2.4 mg doses specifically, we’ve covered that in our 7.2 mg vs 2.4 mg comparison.
How absorption differs
Peptide drugs like semaglutide are normally broken down in the stomach before they can be absorbed.
The two injections avoid this by going under the skin, where most of each dose reaches the bloodstream over several days.
The pill’s absorption is much less efficient, even with the SNAC absorption enhancer; only around 1% of each oral dose reaches the bloodstream.
At 25 mg taken every day, that 1% is enough to produce a meaningful effect.
The pill is also more sensitive to small disruptions than the injection.
Eating too soon after the pill, drinking more than 120 ml of water with it, or taking it with another oral medication can all reduce how much semaglutide reaches the bloodstream that day. Neither injection has this problem.
Across a 64-week trial, these small disruptions average out, and the weight-loss result still ends up close to the 2.4 mg injection.
In day-to-day use, the pill works best when the morning routine is consistent.
The lower-dose oral semaglutide approved for type 2 diabetes (Rybelsus 7 mg and 14 mg) produces only 3 to 4 kg of weight loss because the daily dose isn’t high enough to offset low absorption.
A 25 mg daily dose roughly matches the 2.4 mg weekly injection in terms of weight outcomes. Matching the 7.2 mg injection in an oral formulation would require a higher dose, which hasn’t been approved yet.
Side effects compared
All three formats share the same side-effect profile because the drug is the same.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. They tend to be worse in the first few weeks while the dose is being increased, then settle.
In STEP 1, nausea affected 43.9% of people on the 2.4 mg injection, vomiting 24.5%, diarrhoea 29.7%, and constipation 24.2%.
About 4.3% stopped the medication because of side effects, compared with 0.7% on placebo.2
In STEP UP, gastrointestinal side effects were more common on 7.2 mg than on 2.4 mg, in line with the higher dose.
Stopping the medication due to side effects was higher than with the 2.4 mg dose, though most participants reached the maintenance dose.
The longer dose-escalation schedule (28 weeks for 7.2 mg vs 16 weeks for 2.4 mg) is designed to give the body more time to adjust at each step.1
STEP UP also reported altered skin sensation (tingling, prickling, numbness, or reduced sensitivity) in around 22% of participants on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo. It’s usually mild and resolves on its own, but it’s one of the few side effects that genuinely separates the two doses.1
In OASIS 4, nausea affected 46.6% of people on the pill, vomiting 30.9%, and the overall rate of any gastrointestinal side effect was 74.0%. About 6.9% stopped the medication because of side effects, compared with 5.9% on placebo.3
Side-effect rates are slightly higher with the pill than with the 2.4 mg injection, and slightly higher again with the 7.2 mg injection. For most people, they become tolerable once the dose is stable.
Two side-effect differences across the formats:
- Injection-site reactions: redness, soreness, or itching where the injection was given. These affect a small minority of patients on either injection dose and are usually mild. The pill removes this risk entirely.
- Daily versus weekly rhythm: with the weekly injection, any side effects tend to be worse in the day or two after the shot, then settle for the rest of the week. With the daily pill, the effects are more even across the days.
Serious adverse events such as pancreatitis, gallbladder problems, and (rarely) acute kidney injury are listed for all three formats. The risk profile follows the drug, not the format or the dose.
Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take Wegovy in any form.
The morning fasting rule vs the injection day
The biggest day-to-day difference between the pill and either injection is the morning routine the pill requires.
The 2.4 mg and 7.2 mg injections have the same once-a-week schedule and identical timing rules; the only difference between them is the dose in the pen.
The Wegovy pill must be taken first thing in the morning on an empty stomach, with no more than 120 ml of plain water.
After taking the medication, you need to wait 30 minutes before eating, drinking anything else (including tea or coffee), or taking other oral medications.4
If you take the pill with food, with more than 120 ml of water, or eat too soon afterwards, much less of the dose is absorbed.
If you don’t follow the dosing rules exactly as described every now and again, it’s fine. But if you consistently take the pill outside of the recommended dosing guidance, it won’t be as effective.
For many people, the 30-minute window fits around the morning routine without difficulty: take the pill when you wake up, shower, get dressed or sort the children, then have breakfast.
For others, particularly those whose morning starts with a coffee or who take medications that require food, the timing can be hard to keep up with every day.
The Wegovy injection (at either dose) doesn’t change your morning routine.
The dose is taken once a week, on any day, at any time, with or without food. Most people pick a day and stick to it.
The whole routine is one injection in the thigh, abdomen, or upper arm, taking around a minute.
If you’re worried about injecting yourself, the Wegovy pen is preloaded and designed to be self-administered.
The needle is short and very fine, and most people find the discomfort is less than they expected after the first few weeks.
Needle anxiety is a reason why some people prefer the pill, but for most people, the injection becomes easier with practice.
UK availability and what we know about cost
The Wegovy 2.4 mg injection has been available in the UK since 2023, through both private prescriptions and a limited number of NHS specialist weight-management services.
Private monthly prices for the 2.4 mg maintenance dose currently range from around £150 to £299, depending on the pharmacy and any first-month discounts.
The Wegovy 7.2 mg injection was approved by the MHRA in January 2026 (initially as a stacked-dose regimen using the 2.4 mg pen), with a single-injection 7.2 mg pen approved in April 2026.1
The 7.2 mg dose is available through private providers. NHS access through a separate NICE appraisal is likely later in 2026 or in 2027.
Private pricing for 7.2 mg runs slightly above the 2.4 mg dose, although the exact figure varies by provider.
The Wegovy pill isn’t yet licensed in the UK. The MHRA is reviewing Novo Nordisk’s submission, with a decision expected in late 2026.
If approved, a private launch would likely follow within a few months. NHS access would come later, after a separate NICE appraisal of cost-effectiveness, which usually takes around a year after MHRA approval.
UK pricing for the pill hasn’t been confirmed. In the U.S., the pill launched in January 2026 at $149 a month for the starting dose, rising to $299 for the highest dose.
The injection is higher in both doses ($349 for 2.4 mg, $399 for 7.2 mg), so the pill launched at a lower price than either injection, rather than at a similar price.
Whether UK pricing follows the same pattern isn’t yet known.
| Format |
Monthly cost without insurance: U.S. (UK private in brackets) |
| Wegovy pill (starting dose, 1.5 mg) |
$149 (not yet available in UK) |
| Wegovy pill (maintenance dose, 25 mg) |
$299 (not yet available in UK) |
| Wegovy 2.4 mg injection |
$349 (£150-£299) |
| Wegovy 7.2 mg injection |
$399 (~£349) |
For now, the practical question for anyone in the UK isn’t which of the three formats to choose. It’s whether to start on an injection now or wait for the pill.
If the medication is clinically appropriate and you’re ready to make the changes that come with it, both injection doses are available.
If you’d strongly prefer the pill and your weight has been stable for a few months, holding on for the UK launch is reasonable. We’ve covered the UK launch timeline in more detail in our Wegovy pill UK guide.
If you’re choosing between Wegovy and Mounjaro at either dose, our Wegovy vs Mounjaro guide covers the broader injection comparison.
Second Nature has worked with the NHS since 2017, combining Wegovy and Mounjaro with structured habit support to ensure the weight loss lasts. Take our 3-minute eligibility quiz, and a clinician will review your answers.
Who might prefer each option
The 7.2 mg injection might suit you better if:
- You want the highest average weight loss available from a Wegovy product
- You’re comfortable with the longer dose-escalation schedule (around 28 weeks to reach maintenance) and the slightly higher side-effect rates that come with the higher dose
- You’ve plateaued on the 2.4 mg dose, and your prescriber agrees an increase is appropriate
The 2.4 mg injection might suit you better if:
- The 14.9% average weight loss is within your target weight loss
- You’d prefer a shorter dose escalation (around 16 weeks) and the more established side-effect profile of the 2.4 mg dose
- You’re managing a condition or routine that makes the gentler escalation more practical
The pill might suit you better if:
- You strongly dislike or have a phobia of needles, and have tried injections before without getting comfortable with them
- You travel often for work and want to avoid the storage and transport requirements of an injectable pen (Wegovy pens are kept refrigerated until first use)
- You already take other oral medications at consistent morning times, so a 30-minute morning window fits into your existing schedule
- You’re medically eligible but not ready to start now, and your weight has been stable while you wait for UK approval
If you’re weighing the pill against another oral GLP-1 like Foundayo (orforglipron) rather than an injection, our Wegovy pill vs Foundayo guide covers that comparison in more detail.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
It depends on the dose of injection. In trials, the pill produced a slightly smaller average weight loss than the 2.4 mg injection (13.6% vs 14.9%), and substantially less than the 7.2 mg injection (13.6% vs 20.7%).
Both injection doses and the pill produce meaningful results compared with lifestyle changes alone.
How does Wegovy 7.2 mg compare to the pill and the 2.4 mg dose?
The 7.2 mg injection produced an average weight loss of 20.7% over 72 weeks in STEP UP, about 6 percentage points higher than the 2.4 mg injection (14.9%) and about 7 percentage points higher than the Wegovy pill (13.6%).
It’s the format with the highest average weight loss of the three, though it has a longer dose-escalation schedule and slightly higher rates of side effects than the 2.4 mg injection.
Can I switch from one Wegovy format to another?
Switching between the 2.4 mg and 7.2 mg doses is something your prescriber may suggest if you’ve plateaued on the lower dose.
Switching from either injection to the pill isn’t possible in the UK yet because the pill isn’t licensed.
Once the MHRA approves it, switching will be decided with your prescriber, with timing and dose conversion guided by their clinical advice.
When will the Wegovy pill be available in the UK?
The MHRA is currently reviewing Novo Nordisk’s submission, with a decision expected in late 2026. A private launch in the UK would likely follow shortly afterwards, with NHS access (via NICE) coming later.
For more details, see our Wegovy pill UK guide.
Can I drink coffee in the morning if I’m on the Wegovy pill?
Yes, but you’ll need to wait 30 minutes after taking the pill before having coffee, tea, or any drink other than the small amount of plain water taken with the tablet.
For people whose morning starts with coffee, the simplest solution is to take the pill as soon as you wake up, then have your coffee with breakfast half an hour later.
Do the heart-protective benefits of Wegovy apply to all three formats?
The 2.4 mg Wegovy injection is licensed in the UK to reduce the risk of cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and obesity, based on the SELECT trial.
The 7.2 mg injection and the pill use the same drug, so cardiovascular benefits are biologically expected, but the regulatory approval is separate for each format and would need its own evidence.
What happens if I miss a dose of the Wegovy pill?
Skip the missed dose and take the next one at the normal time the next morning. Don’t double up.
Missing the occasional day won’t undo your progress, but missing several days in a row will reduce the medication’s effect and may mean you experience more side effects when you restart.
Is one Wegovy format safer than the others?
All three formats share the same safety profile because the drug is the same.
Side-effect rates are slightly higher with the pill than with the 2.4 mg injection, and slightly higher again with 7.2 mg, but discontinuation rates aren’t dramatically different.
No format is meaningfully safer than the others; the choice comes down to which routine and dose your prescriber thinks is right for you.
Will the Wegovy pill be cheaper than the injection in the UK?
This isn’t confirmed yet because the pill isn’t licensed in the UK.
In the U.S., the pill launched at around $149 a month for the starting dose, rising to $299 a month for the highest dose.
The cash-pay price for the injection at the same point was around $399 a month, so the pill was meaningfully cheaper than the injection at launch.
Whether UK pricing follows the same pattern isn’t yet known. For anyone in the UK planning costs over the next 6 to 12 months, the realistic comparison is between the two injection doses currently available.
Take home message
The three Wegovy formats use the same drug, work the same way, and differ mainly in dose, delivery, and the amount of weight loss they produce on average.
The 7.2 mg injection has the highest average weight loss of 20.7%; the 2.4 mg injection and the pill support similar average weight loss at 14.9% and 13.6%, respectively.
In the UK, as of May 2026, the practical choice is between starting on the 2.4 mg or 7.2 mg injection now or waiting for the pill’s expected MHRA approval later in the year.
No format is meaningfully safer than the others; side-effect profiles are broadly similar across the three, and the daily routine is the biggest day-to-day difference (the pill has a morning fasting rule, the injections don’t).
Second Nature has worked with the NHS since 2017, combining Wegovy and Mounjaro with structured habit support designed around the balanced plate model: half vegetables, a quarter protein, a quarter complex carbohydrates, plus a serving of fat.
Our published research found an average weight loss of 19.1% at 12 months in active subscribers on a GLP-1-supported programme, with 77.7% achieving at least 10% weight loss.6
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
